Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

NCRI 2018 | Modelling GBM: Improving the translation between preclinical data and effective treatments

Anthony Chalmers • 15 Nov 2018
NCRI 2018
Brain Tumor Glioblastoma Glioma

In this interview, Anthony Chalmers, BM, BCh, FRCR, PhD, FRCP, from the University of Glasgow, Glasgow, UK, discusses the design and delivery of preclinical projects evaluating specific radiotherapy-drug combinations for glioblastoma (GBM). Speaking at the 2018 National Cancer Research Institute (NCRI) Cancer Conference, held in Glasgow, UK, Prof. Chalmers discusses approaches in trying to improve the survival rates seen in patients, focusing on future avenues for the improved modelling of GBM.

More from Anthony Chalmers

Optimizing GBM tumor targeting through radiotherapy and DNA repair inhibition
3:48
Optimizing GBM tumor targeting through radiotherapy and DNA repair inhibition
Anthony Chalmers • 26 Apr 2023
Optimizing GBM tumor targeting through radiotherapy and DNA repair inhibition
3:48
Optimizing GBM tumor targeting through radiotherapy and DNA repair inhibition
Anthony Chalmers • 26 Apr 2023
Unmet needs in glioblastoma treatment
1:18
Unmet needs in glioblastoma treatment
Anthony Chalmers • 25 Apr 2023
Pain in mesothelioma
0:36
Pain in mesothelioma
Anthony Chalmers • 27 Apr 2023

Related Videos

Practical challenges of adoptive neoantigen-specific T-cell immunotherapy in MGMT-u glioblastoma
0:58
Practical challenges of adoptive neoantigen-specific T-cell immunotherapy in MGMT-u glioblastoma
Tolga Tuncer • 30 May 2026
TVI-AST-008: adoptive neoantigen-specific T-cell immunotherapy in MGMT-u glioblastoma
1:51
TVI-AST-008: adoptive neoantigen-specific T-cell immunotherapy in MGMT-u glioblastoma
Tolga Tuncer • 30 May 2026
Phase II trial of lutetium-177 dotatate in advanced intracranial meningioma
1:32
Phase II trial of lutetium-177 dotatate in advanced intracranial meningioma
Sylvia Kurz • 31 May 2026
Mechanism of 177Lu-dotatate in SSTR2-positive meningioma
1:04
Mechanism of 177Lu-dotatate in SSTR2-positive meningioma
Sylvia Kurz • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals